Among the described PAH models, the mouse model that combines hypoxia exposure with the inhibition of vascular endothelial growth factor receptor (VEGF) using Semaxanib (SU5416) has been used to study several of the etiologic mechanisms involved in cell hyperproliferation (14, 15). This evidence concerns the gene VEGFA and pulmonary arterial hypertension.